130.23
price up icon0.52%   +0.68
after-market  시간 외 거래:  130.25  0.02   +0.02%
loading

Merck & Co Inc 주식(MRK)의 최신 뉴스

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

pulisher
Zacks Investment Research

Jim Cramer Advises Investors To Brace For Economic Slowdown, Shares Tips To Maintain Balanced Portfolio: 'I'm Not Telling You To Relax'

pulisher
Benzinga

A Look at Pharma ETFs Post Q1 Earnings

pulisher
Zacks Investment Research

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?

pulisher
Zacks Investment Research

SCHD: A Must-Have In Every Dividend Portfolio

pulisher
Seeking Alpha

Here's Why Merck (MRK) is a Strong Momentum Stock

pulisher
Zacks Investment Research

Job Market Cools In April: Payrolls Miss Forecasts, Wages Rise Less Than Expected (UPDATED)

pulisher
Benzinga

Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y

pulisher
Zacks Investment Research

Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect

pulisher
Zacks Investment Research

Merck Shines in Q1 2024 Earnings Surge

pulisher
The Motley Fool

Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates

pulisher
Zacks Investment Research

Merck (MRK) Q1 2024 Earnings Call Transcript

pulisher
The Motley Fool

AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up

pulisher
Zacks Investment Research

Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?

pulisher
Benzinga

Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales

pulisher
Zacks Investment Research

Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

pulisher
Zacks Investment Research

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie

pulisher
Zacks Investment Research

US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst

pulisher
Benzinga

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

pulisher
Zacks Investment Research

4 Large Drug Stocks to Hold on to Amid Industry Challenges

pulisher
Zacks Investment Research

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

pulisher
Zacks Investment Research

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

pulisher
Zacks Investment Research

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

pulisher
Zacks Investment Research

Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS

pulisher
Zacks Investment Research

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week

pulisher
Benzinga

Wall Street Breakfast: The Week Ahead

pulisher
Seeking Alpha

Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline

pulisher
Zacks Investment Research

Unveiling 17 Analyst Insights On Merck & Co

pulisher
Benzinga

Merck (MRK) Reports Next Week: Wall Street Expects Earnings Growth

pulisher
Zacks Investment Research

Merck (MRK) Advances While Market Declines: Some Information for Investors

pulisher
Zacks Investment Research

Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel

pulisher
Zacks Investment Research

Better Growth Play: Merck or The Vanguard Growth Index Fund?

pulisher
The Motley Fool

Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.

pulisher
The Motley Fool

1 New Green Flag for Moderna and Merck Stock

pulisher
The Motley Fool

Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade

pulisher
Zacks Investment Research

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says

pulisher
Benzinga

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

pulisher
Zacks Investment Research

Company News for Apr 10, 2024

pulisher
Zacks Investment Research

Corcept (CORT) Completes Enrollment in Ovarian Cancer Study

pulisher
Zacks Investment Research

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)

pulisher
Zacks Investment Research

2 Dividend Stocks to Buy and Hold Forever

pulisher
The Motley Fool

Down 75%. Is Agenus Stock a Buy on the Dip?

pulisher
The Motley Fool

Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

pulisher
Zacks Investment Research

eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails

pulisher
Zacks Investment Research

Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

pulisher
Zacks Investment Research

Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate

pulisher
Zacks Investment Research

Kintara (KTRA) Stock Soars on Merger Agreement With TuHURA

pulisher
Zacks Investment Research

Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up

pulisher
Zacks Investment Research

Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug

pulisher
Zacks Investment Research

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

pulisher
Zacks Investment Research
drug_manufacturers_general JNJ
$149.85
price up icon 0.60%
$160.40
price down icon 0.03%
drug_manufacturers_general NVS
$100.21
price up icon 0.61%
$312.86
price up icon 1.81%
drug_manufacturers_general PFE
$28.18
price down icon 0.32%
자본화:     |  볼륨(24시간):